<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The preconception office visit</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The preconception office visit</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The preconception office visit</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce A Sackey, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah Blazey-Martin, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preconception care is a broad term that refers to the process of identifying behavioral, environmental, biomedical, and social risks to an individual's fertility and pregnancy outcome with the goal of reducing these risks through education, counseling, and appropriate intervention [<a href="#rid1">1</a>].</p><p>Barriers to providing preconception care at the office level include time constraints due to competing priorities within the practice setting, lack of resources to assist with conveying information, and lack of adequate reimbursement for screening tests and counseling [<a href="#rid2">2</a>]. Preconception care screening tools and online informational resources can help with some of these logistics. </p><p>At the patient level, it is important to recognize that most females do not schedule a preconception care visit. Factors that facilitate uptake of preconception care include adequate health insurance coverage, the availability of patient informational resources such as brochures and handouts, and waiting room posters outlining the benefits and availability of preconception care consultations. Preconception care may not be an option for patients in some resource-limited areas. In Malawi, for example, it is not a key component of maternal and child health policy. In a study of over 4000 pregnant individuals, nearly two-thirds took no actions to prepare for their pregnancies and among the one-third who did, eating more healthily (72 percent) and saving money (43 percent) were the most common forms of preparation [<a href="#rid3">3</a>].</p><p>This topic will discuss preconception care in cisgender women. Prenatal care is reviewed separately (see  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment"</a> and  <a class="medical medical_review" href="/z/d/html/83303.html" rel="external">"Prenatal care: Second and third trimesters"</a>). Reproductive planning in sexual minority women (eg, lesbian, gay, bisexual, transgender, queer, and other women, or LGBTQ+) is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5426.html" rel="external">"Sexual and gender minority women (lesbian, gay, bisexual, transgender, plus): Medical and reproductive care", section on 'Reproductive health and parenting issues'</a> and  <a class="medical medical_review" href="/z/d/html/5426.html" rel="external">"Sexual and gender minority women (lesbian, gay, bisexual, transgender, plus): Medical and reproductive care", section on 'Prevention of unintended pregnancy'</a>.)</p><p class="headingAnchor" id="H15600180"><span class="h1">TARGET POPULATION</span><span class="headingEndMark"> — </span>Preconception care should be an essential part of primary and preventive care for all females of childbearing potential who present for a periodic health examination [<a href="#rid1">1,4,5</a>], whether or not they are currently interested in conceiving. In addition to the periodic health evaluation, potential opportunities for preconception care occur during many nonemergency health care encounters, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Premarital office visit</p><p class="bulletIndent1"><span class="glyph">●</span>Contraception counseling and provision</p><p class="bulletIndent1"><span class="glyph">●</span>After a negative pregnancy test</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for sexually transmitted disease or vaginal infection</p><p class="bulletIndent1"><span class="glyph">●</span>Postpartum office visit</p><p class="bulletIndent1"><span class="glyph">●</span>Office visit related to pregnancy termination</p><p></p><p>Routinely addressing preconception issues in all females of childbearing potential is important for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Although many females intend to obtain preconception evaluation and counseling before attempting pregnancy, almost 50 percent of pregnancies in the United States are unintended [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For prevention of congenital anomalies, preconception intervention (eg, <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation, avoidance of alcohol and some medications) is more important than prenatal intervention since as many as 30 percent of pregnant individuals begin traditional prenatal care in the second trimester (≥14 weeks 0 days of gestation), which is after the primary period of organogenesis (between 3 and 10 weeks of gestation)  (<a class="graphic graphic_figure graphicRef56642" href="/z/d/graphic/56642.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some interventions can take months to achieve the desired result (eg, optimization of medical conditions, substantial weight loss).</p><p></p><p>Omission of preconception counseling and intervention in females of childbearing potential who state that they are not planning to become pregnant may explain, in part, why unintended pregnancies are associated with more adverse maternal and infant outcomes than intended pregnancies [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1096982151"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Ideally, the patient and their clinician create a reproductive health plan, which will be reviewed and revised, as needed, at each visit. As part of that plan, they should be asked about their intention to become pregnant and offered contraception that meets their current contraceptive needs while taking into account the timing of a planned first or subsequent pregnancy ("Would you like to become pregnant in the next year?"). Contraception should continue to be addressed at all medical visits of reproductive-age individuals of childbearing potential.</p><p>Primary care teams should be able to perform a basic preconception assessment, provide basic preconception education, and offer appropriate recommendations for intervention, as described below [<a href="#rid8">8-10</a>]. Situations beyond the clinician's expertise should prompt consideration of referral to a genetic counselor and/or other specialty care. Coordination of care among these clinicians is an important component of effective intervention.</p><p class="headingAnchor" id="H378031"><span class="h2">Resources</span><span class="headingEndMark"> — </span>Informational resources on preconception care are available online at no cost from several sources, including:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpreconception%2Findex.html&amp;token=jxIGUyCAq9SA53Rcyh1B57h6ZfHpJJsiPkCapbCXjrj0Kyv2kVz8%2FHMWKFaObptH%2FrTKo1q2lmQW5REOFkhcBw%3D%3D&amp;TOPIC_ID=448" target="_blank">Centers for Disease Control and Prevention</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.marchofdimes.org%2Fpregnancy%2Fyour-checkup-before-pregnancy.aspx&amp;token=%2F%2FkKKyWzzf5WIKfYo2bJT%2FnO0FOPhlAu7tk3E%2BBBbaenF4BWZ9sjHWtjSH%2BDQM7BN%2BKelfl5N0S03DHgZSCG3hE1SAVw0Iqh4ptQQ4gcaLE%3D&amp;TOPIC_ID=448" target="_blank">March of Dimes</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fclinical%2Fclinical-guidance%2Fcommittee-opinion%2Farticles%2F2019%2F01%2Fprepregnancy-counseling&amp;token=lEp0J4Knd4SUWX16atXSospiCws2O2SPcq1CtitcKagFV72D8MC%2Fkd1VfjFF%2FgpX7Ev%2Fk95IHlGRdkiRUwK8xZZglprF3%2Fzcv2%2FxKdidfe3J79h1LdW%2FMsJWBSBeC82Q&amp;TOPIC_ID=448" target="_blank">American College of Obstetricians and Gynecologists</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fperinatalfoundation.org%2F&amp;token=HkP7O6qD%2FSDfuzU%2BZnChJXRZv9wFUIEaV9VXGxOYD%2Bxi%2BQnV4TuAiyrih6a0jx5m&amp;TOPIC_ID=448" target="_blank">Perinatal Foundation</a></p><p></p><p class="headingAnchor" id="H12056719"><span class="h1">GOALS</span><span class="headingEndMark"> — </span>The three major goals of preconception care are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Identify potential risks to the mother, fetus, and pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educate the individual about these risks, options for intervention and management to reduce risk, and reproductive alternatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiate interventions to provide optimum maternal, fetal, and pregnancy outcomes. Interventions include motivational counseling, disease optimization, and specialist referral.</p><p></p><p>There is limited evidence as to the best means for achieving these goals [<a href="#rid1">1,11-13</a>].</p><p class="headingAnchor" id="H6"><span class="h1">RISK ASSESSMENT AT THE PRECONCEPTION OFFICE VISIT</span><span class="headingEndMark"> — </span>The key task in risk assessment is to obtain a thorough history. Several paper and computerized questionnaires and record forms are commercially available for this purpose (see <a class="local">'Resources'</a> above). Patient education and medical interventions can be initiated based on this information.</p><p class="headingAnchor" id="H192320213"><span class="h2">Age</span><span class="headingEndMark"> — </span>As maternal age increases, the risks for infertility, fetal aneuploidy, miscarriage, gestational diabetes, preeclampsia, and stillbirth also increase [<a href="#rid14">14</a>]. Individuals should be aware of these risks and the consequences of delaying conception until they are in their 30s or 40s, and consider this in their reproductive health plans. (See  <a class="medical medical_review" href="/z/d/html/421.html" rel="external">"Effects of advanced maternal age on pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/454.html" rel="external">"Management of pregnancy in patients of advanced age"</a>.)</p><p>Advanced paternal age also has some risks for offspring. (See  <a class="medical medical_review" href="/z/d/html/415.html" rel="external">"Effect of advanced paternal age on fertility and pregnancy"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">History</span><span class="headingEndMark"> — </span>A thorough medical history is a good starting point for discussing how pregnancy can affect maternal health and the effect of maternal health and behavior on the fetus and pregnancy. </p><p class="headingAnchor" id="H423924291"><span class="h3">Components</span><span class="headingEndMark"> — </span>Guidelines generally target the following areas for preconception risk assessment [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic medical problems (including obesity) – Although it makes intuitive sense that identifying and treating medical conditions, including obesity and mental health issues, prior to pregnancy is beneficial, few randomized trials have evaluated the efficacy of preconception health promotion interventions for improving pregnancy outcome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications known to be teratogens – A key component of medical assessment is to identify use of medications (including over-the-counter and prescription drugs) that are teratogenic and may be stopped (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>), should be stopped (eg, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>), or can be changed to one that is safer for the pregnant individual or fetus (eg, extended-release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> instead of <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a>). It is especially important to elicit exposure to dietary supplements (eg, herbal supplements), as patients may not perceive them as medications that can be harmful to the fetus. Information on the pregnancy implications of drugs is available in the UpToDate drug database and from other resources. However, human teratogenic risk is undetermined for 98 percent of the drugs approved for human use and only approximately 30 drugs are considered to be proven as safe in pregnancy. Most of these are vitamins, minerals, electrolytes, and hormone replacement (eg, <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) at physiological doses. Therefore, the potential risk of medication use has to be considered on a case-by-case basis in terms of the harm of discontinuing the drug and the availability of alternative drugs. (See <a class="local">'Resources for information on potential teratogens'</a> below.)</p><p></p><p class="bulletIndent1">Medications used by the biologic father may affect the number and quality of sperm and thus male fertility, but a causal relationship with congenital anomalies is unusual and poorly defined [<a href="#rid15">15</a>]. Males exposed to cytotoxic or mutagenic substances are generally advised to wait six months (at least two sperm cycles) before attempting conception, but the range varies and depends on the specific drug [<a href="#rid16">16</a>]. For example, males taking <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> can have the drug in their semen and are advised to use a latex or synthetic condom during any sexual contact with females of childbearing potential and for up to 28 days following discontinuation of therapy. Males taking <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> can have damage to sperm through DNA alterations; therefore, this medication should be avoided for three months before conception in males attempting to father a child [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reproductive history  (<a class="graphic graphic_table graphicRef78008" href="/z/d/graphic/78008.html" rel="external">table 1</a>) – The gynecologic and obstetric histories are important for identifying factors that may contribute to infertility or complications in a future pregnancy and initiating appropriate intervention to reduce or eliminate these risks, if possible [<a href="#rid18">18</a>]. Use of contraception should be discussed to help ensure that pregnancy occurs at an appropriate time with respect to both personal choice and medical optimization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic risks and conditions and family history (eg, increasing maternal age is associated with increasing risk for aneuploidy in offspring) (see  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a> and  <a class="medical medical_review" href="/z/d/html/114595.html" rel="external">"Preconception and prenatal panethnic expanded carrier screening"</a> and  <a class="medical medical_review" href="/z/d/html/428.html" rel="external">"Preconception and prenatal carrier screening for genetic disorders more common in people of Ashkenazi Jewish descent and others with a family history of these disorders"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substance use, including nicotine-containing products, tetrahydrocannabinol (THC), alcohol, opioids, and nonprescribed drugs (see  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a> and  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">"Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious diseases and vaccinations (see  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutrition (type of diet and intake, vitamins, supplements) and weight management (see <a class="local">'Diet and supplements'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical activity, exercise routine (see  <a class="medical medical_review" href="/z/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Environmental hazards and toxins (eg, nonuse of safety belts; exposure to firearms, occupational hazards, infection; travel; hobbies; pets) (see <a class="local">'Environmental exposures'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Social and mental health concerns (eg, depression, social support, intimate partner violence and other safety issues, unstable housing, food insecurity) (see <a class="local">'Psychosocial issues'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major surgical procedures.</p><p></p><p class="headingAnchor" id="H7473890"><span class="h3">Environmental exposures</span><span class="headingEndMark"> — </span>Questions about the individual's work, travel, hobbies, pets, and home environment can identify potentially toxic exposures (including endocrine disruptors), such mercury, lead, pesticides, air pollution, household cleaning products, unsafe sources of water, plastics used for food storage, and infection (eg, Zika, Chagas disease) [<a href="#rid19">19</a>]. In addition to occupational exposures, mercury may be found in fish and skin-lightening creams, and lead may be detected in paint (pre-1970), imported cosmetics/food additives/medicine, and clay [<a href="#rid20">20</a>]. Of note, there is no convincing evidence that exposure to common sources of electromagnetic field radiation, such as computer monitors, electric blankets, heated water beds, cell phones, and microwave ovens, is harmful [<a href="#rid21">21</a>].</p><p>In the United States, the Occupational Safety and Health Administration (OSHA) sets and enforces standards requiring employers to provide a workplace free from recognized hazards likely to cause serious physical harm. This information should be available at the patient's workplace. (See  <a class="medical medical_review" href="/z/d/html/2749.html" rel="external">"Overview of occupational and environmental health"</a> and  <a class="medical medical_review" href="/z/d/html/5447.html" rel="external">"Overview of occupational and environmental risks to reproduction in females"</a> and  <a class="medical medical_review" href="/z/d/html/439.html" rel="external">"Working during pregnancy"</a>.)</p><p>Cytomegalovirus, Zika, rubella, syphilis, toxoplasmosis, herpes simplex virus, and varicella are infections with teratogenic potential. Congenital Chagas disease can cause early or late morbidity in offspring. Modes of transmission are discussed in individual topic reviews on each infection. Clinicians and patients should be aware of the places where Zika is endemic and the ways that Zika virus is transmitted (eg, mosquito bite, sex) and take appropriate precautions to avoid Zika virus infection during pregnancy. While COVID-19 is a relatively new virus, it does not appear to be associated with congenital anomalies. (See  <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">"Zika virus infection: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/107211.html" rel="external">"Zika virus infection: Evaluation and management of pregnant patients"</a> and  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a>.)</p><p class="headingAnchor" id="H12057526"><span class="h3">Resources for information on potential teratogens</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nlm.nih.gov%2F&amp;token=lblfowwGB6QwC91WNuiIf%2FF4aKcTuKAb%2F1WYvLNH%2FRmvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=448" target="_blank">National Library of Medicine (NLM)</a></p><p class="bulletIndent1">Bethesda, MD</p><p class="bulletIndent1">800-638-8480</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Freprotox.org%2F&amp;token=Ryuc2NABJGKCQZO0cGQLQ%2BlIiapLy0sf7zMh%2FrkID0g%3D&amp;TOPIC_ID=448" target="_blank">Reproductive Toxicology Center</a></p><p class="bulletIndent1">REPROTOX</p><p class="bulletIndent1">Columbia Hospital for Women Medical Center</p><p class="bulletIndent1">Washington, DC</p><p class="bulletIndent1">202-293-5137</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdeohs.washington.edu%2Fteris%2F&amp;token=RkqhEFptHofdd7816QG%2B7MPc6vbj2UCuaY0DDLsFjBB6lpH7znzLPqgN%2B06w6UrL&amp;TOPIC_ID=448" target="_blank">Teratogen Information System</a></p><p class="bulletIndent1">TERIS and Shepard's Catalog of Teratogenic Agents</p><p class="bulletIndent1">Seattle, WA</p><p class="bulletIndent1">206-543-2465</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fscience-research%2Fwomens-health-research%2Flist-pregnancy-exposure-registries&amp;token=m85hvh399frcnRUA8LL7wUaalJjxXmrulQM%2FCe1nhXmAIWukUQRgebfu4gphHpzx2iiEuG4sc3Hf0G4p3%2FaYpXIMyYzTgAExs7X%2BQaN9hOPxcwPiCnEuAs8KHeZ6uNDm&amp;TOPIC_ID=448" target="_blank">Pregnancy Exposure Registries</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.teratology.org%2F&amp;token=JUDE1kNBgjGYrfVo9FSf0PqB3q1oTVJ5EY2Iqmk7QDeUGRU1UoZYLtazZMdLoqep&amp;TOPIC_ID=448" target="_blank">The Teratology Society's</a> <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmothertobaby.org%2Ffact-sheets%2F&amp;token=cjWcuFd4xzPwN3syululi9m3vA1yuDwyC1U99MUOHAfyR2psJ2H2dL9kFUB%2F75aA&amp;TOPIC_ID=448" target="_blank">MotherToBaby fact sheets</a></p><p class="bulletIndent1">866-626-6847 </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pehsu.net%2Faboutus.html&amp;token=kgWnuLuwd5ywHVQww%2BY9egcttjH%2BpPpP8MsEH7P%2BkPh9AF%2BI8AZycJJWrr2Wyi3D&amp;TOPIC_ID=448" target="_blank">Pediatric Environmental Health Specialty Units (PEHSU)</a></p><p></p><p class="headingAnchor" id="H12057766"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>In healthy females, a reasonable preconception physical examination includes assessment of the heart, breasts, lungs, thyroid, abdomen, mouth, and genital tract, as well as blood pressure and body mass index (BMI). This examination is a pragmatic approach to detection of the most common conditions that can affect maternal health and pregnancy outcome.</p><p class="headingAnchor" id="H12057772"><span class="h2">Laboratory assessment</span></p><p class="bulletIndent1"><span class="glyph">●</span>Human immunodeficiency virus (HIV) counseling and screening are recommended for all females planning pregnancy (patients may opt out) because treatment of maternal HIV infection can reduce the risk of congenital infection [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for gonorrhea, chlamydia, syphilis  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 2</a>); hepatitis B and C  (<a class="graphic graphic_table graphicRef55052" href="/z/d/graphic/55052.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef98092" href="/z/d/graphic/98092.html" rel="external">table 4</a>); and other sexually transmitted infections is performed according to standard guidelines. Depending on the disease, untreated infections can cause subfertility/infertility, as well as congenital infection and medical and pregnancy complications [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a> and  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Hepatitis C'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Document rubella immunity or lack of immunity, if not previously performed. Evidence of immunity consists of laboratory evidence of rubella immunity, laboratory confirmation of disease, documentation of vaccination with at least one dose of live rubella virus-containing vaccine at age ≥12 months [<a href="#rid22">22</a>]. Rubella infection in pregnancy can have serious adverse effects on the fetus and can be prevented by prepregnancy immunization (immunization with a live vaccine cannot be performed in pregnancy). (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Preconception immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Document varicella immunity or lack of immunity, if not previously performed. Evidence of immunity consists of a clinician's diagnosis of varicella or verification of history of varicella disease, documented vaccination, or laboratory evidence of immunity. Varicella infection in pregnancy can have serious adverse effects on the fetus and can be prevented by prepregnancy immunization (immunization with a live vaccine cannot be performed in pregnancy). (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Preconception immunization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screen for Chagas disease in females of reproductive age in the United States who were born in or lived in a region of Mexico or South or Central America with endemic Chagas disease  (<a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 5</a>). Individuals with Chagas disease are often unaware of their infection and its potential seriousness, including maternal cardiovascular and gastrointestinal complications, transmission to the fetus, and hydrops fetalis. Prepregnancy diagnosis and treatment can improve maternal outcomes and prevent mother-to-child transmission. For these reasons, an expert working group now recommends screening for Chagas disease in females of reproductive age in the United States who were born in or lived in a region of Mexico or South or Central America with endemic Chagas disease [<a href="#rid23">23</a>]. Ideally, screening is performed before pregnancy because antitrypanosomal drugs are contraindicated during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/5698.html" rel="external">"Chagas disease: Epidemiology, screening, and prevention", section on 'Screening for chagas disease in nonendemic clinical and community settings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic carrier screening may be based upon the patient's or the potential biologic father's medical history or family history of heritable disease, ethnic origin, or patient request. Ideally carrier screening is performed before pregnancy as it can take considerable time to perform the test, and if appropriate, test the partner and arrange genetic counseling. This information allows individuals planning pregnancy to make informed reproductive decisions about adoption, gestational carrier pregnancy, use of donor sperm, in vitro fertilization with preimplantation genetic testing, avoidance of pregnancy, and prenatal diagnosis [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/428.html" rel="external">"Preconception and prenatal carrier screening for genetic disorders more common in people of Ashkenazi Jewish descent and others with a family history of these disorders"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/463.html" rel="external">"Cystic fibrosis: Carrier screening"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/437.html" rel="external">"Fragile X syndrome: Prenatal screening and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/6146.html" rel="external">"Spinal muscular atrophy", section on 'Pregnancy'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/114595.html" rel="external">"Preconception and prenatal panethnic expanded carrier screening"</a>.)</p><p></p><p class="bulletIndent1">The simplest (but not most sensitive) screening test for hemoglobinopathies is review of red cell indices, as mean corpuscular volume (MCV) &lt;80 fL may indicate that the individual is a carrier. (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Check glycated hemoglobin (A1C) in individuals with pregestational diabetes. Good glucose control (A1C &lt;6.5 percent) in early pregnancy reduces the risk of miscarriage and congenital anomalies, and can take time to achieve. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screen for type 2 diabetes in individuals with risk factors for diabetes  (<a class="graphic graphic_table graphicRef122948" href="/z/d/graphic/122948.html" rel="external">table 6</a>). Screening consists of a fasting plasma glucose, A1C, or both  (<a class="graphic graphic_table graphicRef61853" href="/z/d/graphic/61853.html" rel="external">table 7</a>). (See  <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">"Screening for type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Test for latent tuberculosis in high-risk populations to avoid exposing the fetus to treatment, if indicated, during pregnancy. A <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> or an interferon-gamma release assay (eg, QuantiFERON test) on blood may be used  (<a class="graphic graphic_table graphicRef76107" href="/z/d/graphic/76107.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a> and  <a class="medical medical_review" href="/z/d/html/8005.html" rel="external">"Use of the tuberculin skin test for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="bulletIndent1">Testing for and treatment of latent tuberculosis infection should be pursued in individuals at risk for new infection and individuals at risk for progression from latent to active tuberculosis because of underlying conditions  (<a class="graphic graphic_table graphicRef74584" href="/z/d/graphic/74584.html" rel="external">table 9</a>). A decision to test implies a decision to treat if the test is positive. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Check a serum phenylalanine level if maternal phenylketonuria is known or suspected. Phenylalanine embryopathy can be prevented by dietary restriction of phenylalanine before and during pregnancy. The National Institutes of Health (NIH) Consensus Development statement recommended that plasma phenylalanine levels should be reduced to levels &lt;6 mg/dL (360 micromol/L) at least three months before conception and remain at 2 to 6 mg/dL (120 to 360 micromol/L) during pregnancy [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">"Overview of phenylketonuria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Check a lead level if the patient is at high risk of lead exposure or an increased lead level, given the potential for adverse effects on the mother and fetus. The case definition for an elevated blood lead level for an adult is now defined as ≥5 mcg/dL by the National Institute for Occupational Safety and Health (NIOSH)/CDC's Adult Blood Lead Epidemiology and Surveillance (ABLES) program [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2773.html" rel="external">"Lead exposure, toxicity, and poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Lead level'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxoplasmosis screening is controversial. Although national societies in the United States, Canada, and the United Kingdom advise against routine universal screening for toxoplasmosis during pregnancy, a prepregnancy baseline titer can be useful if screening is performed in patients with occupational exposure, pet cats, or high-risk eating habits. Patients with a negative toxoplasmosis titer should be counseled to avoid changing the cat litter, forgo eating undercooked meat, wear gloves when gardening, and frequently wash food, hands, and food preparation areas. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus infection screening is also controversial. Knowledge of a negative titer in individuals at high risk of exposure (eg, work in child care facilities or dialysis units or have children in day care) may increase their motivation to practice good hygiene and decrease their risk of seroconversion during pregnancy. The highest risk of seroconversion is in mothers who have recently placed a toddler in day care. (See  <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy"</a>.)</p><p></p><p>Standard laboratory and other screening recommendations for the healthy adult population regardless of pregnancy plans are reviewed elsewhere.</p><p class="headingAnchor" id="H20"><span class="h1">INTERVENTIONS</span><span class="headingEndMark"> — </span>Preconception interventions include health promotion education and counseling related to reproductive health risks, optimizing the control of medical disorders, and referral for specialized care, when appropriate. If pregnancy avoidance is desired, then contraceptive options should be discussed and a contraceptive chosen in line with the planned timing of pregnancy. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a> and  <a class="medical medical_review" href="/z/d/html/6767.html" rel="external">"Interpregnancy interval: Optimizing time between pregnancies"</a>.)</p><p>Available evidence, which is primarily observational data, supports an association between preconceptional counseling and positive changes in maternal behavior before pregnancy, particularly with respect to <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> intake, improved glycemic control, and reduction in alcohol intake and cigarettes smoked [<a href="#rid27">27-40</a>]. There is also evidence from randomized trials that the prevalence of congenital anomalies was reduced by preconception care of females with diabetes [<a href="#rid41">41</a>] or epilepsy [<a href="#rid42">42</a>], while a cohort study supported a reduction in embryopathy in females with phenylketonuria who were placed on a strict low phenylalanine diet prior to conception [<a href="#rid43">43</a>]. In a trial in low- and middle-income neighborhoods in India, a package of health, nutrition, water, sanitation and hygiene, and psychosocial care interventions during the preconception period reduced the incidence of low birth weight compared with usual care [<a href="#rid44">44</a>]. In the United States, a secondary analysis of prospectively collected data from females without chronic diseases found that a prepregnancy healthy lifestyle was associated with a substantially lower risk of adverse pregnancy outcomes [<a href="#rid45">45</a>]. However, many individuals are unable to adopt a healthy lifestyle while attempting pregnancy [<a href="#rid46">46,47</a>].</p><p class="headingAnchor" id="H192321026"><span class="h2">Core interventions</span><span class="headingEndMark"> — </span>The following core interventions can reduce the occurrence of congenital anomalies, congenital disease, impaired or excessive fetal growth, and a variety of pregnancy complications (eg, preterm birth, placental abruption) [<a href="#rid27">27,41,48,49</a>]. The evidence for the efficacy of these interventions is discussed in topic reviews on each intervention. Some interventions are effective if begun any time before conception, while glycemic control may take weeks to months to achieve, and substantial weight loss may take years. A recent focus of preconception care is to optimize prepregnancy cardiovascular health (ie, sleep duration, diet, physical activity, smoking cessation, BMI, blood pressure, cholesterol and glucose levels, psychological health), which may reduce the risks of both adverse pregnancy outcome and cardiovascular disease in the individual and their offspring [<a href="#rid50">50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a><strong> supplementation</strong> and intake of folate fortified foods – Supplementation (400 to 800 mcg daily) and intake of fortified foods is recommended to reduce the risk of neural tube defects, and possibly other anomalies. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic control and screening for diabetes comorbidities</strong> <strong>in females with diabetes</strong> – The American Diabetes Association recommends aiming for an A1C &lt;6.5 percent (48 mmol/mol) prior to conception, if safely possible [<a href="#rid51">51</a>]. Euglycemia during pregnancy reduces the risks of congenital anomalies, miscarriage, preeclampsia, macrosomia, preterm birth, and other complications.</p><p></p><p class="bulletIndent1">In addition, females with diabetes who take angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and statins should discontinue use and switch to alternatives (when available) with a better fetal safety profile (eg, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, calcium channel blocker). Most females on oral anti-hyperglycemic drugs should be switched to insulin. If an oral anti-hyperglycemic drug is maintained, it should be <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> or <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients"</a> and  <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Risks in pregnancy and breastfeeding'</a> and  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Glycemic control'</a>.)</p><p></p><p class="bulletIndent1">Evaluation for proliferative retinopathy is also indicated and, if present, should be treated prior to attempts at conception. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management", section on 'Preconception evaluation and management'</a>.)</p><p></p><p class="bulletIndent1">Given the complexity of these issues, preconception care is ideally provided at a multidisciplinary clinic including an endocrinologist, maternal-fetal medicine specialist, registered dietitian nutritionist, and diabetes care and education specialist, when available. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of phenylalanine levels</strong> <strong>in females with phenylketonuria</strong> – Goal is less than 6 mg/dL for at least three months before conception and maintained at 2 to 6 mg/dL (120 to 360 micromol/L) during pregnancy to reduce the risk of embryopathy [<a href="#rid25">25,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/2919.html" rel="external">"Overview of phenylketonuria", section on 'Phenylalanine embryopathy (maternal PKU)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abstinence from alcohol and opioid misuse</strong> – A safe level of alcohol intake during pregnancy has not been determined. Individuals who use alcohol or misuse opioids can be referred to a program for alcohol cessation or methadone- or buprenorphine-assisted treatment. (See  <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a> and  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotine and tetrahydrocannabinol (THC) cessation</strong> – Individuals who are planning pregnancy may be more motivated to stop smoking and/or vaping and to utilize smoking cessation resources. Both nicotine and THC have known negative impacts on pregnancy, but data are limited. (See  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a> and  <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">"Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/122671.html" rel="external">"E-cigarette or vaping product use-associated lung injury (EVALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Up-to-date vaccinations</strong>  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef81508" href="/z/d/graphic/81508.html" rel="external">table 10</a>) – Vaccination protects against maternal and, in turn, congenital infection and provides passive protection to the newborn.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live vaccines (varicella; measle, mumps, rubella) should be administered at least one month prior to pregnancy. (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Preconception immunization'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All individuals who are pregnant or might be pregnant during the influenza season should receive the inactivated influenza virus vaccine as soon as it becomes available and before onset of influenza activity in the community, regardless of their stage of pregnancy. Pregnant individuals with influenza are more likely to develop severe illness and to die than the general population. (See  <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">"Seasonal influenza and pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ideally, the acellular pertussis vaccine is administered during pregnancy, rather than before conception to protect the infant from pertussis before it is eligible for vaccination. Maternal antibody levels wane quickly; vaccination between 27 and 36 weeks of gestation and at least one week before birth maximizes passive antibody transfer to the infant. (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>COVID-19 vaccination is recommended. Pregnancy itself is associated with an increased risk of severe infection and vaccine safety and efficacy have been established. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues", section on 'Vaccination in people planning pregnancy and pregnant or recently pregnant people'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight reduction (or gain) to achieve a normal body mass index (BMI)</strong> – Obesity is associated with infertility; several adverse pregnancy outcomes, including congenital anomalies; and an increased risk of maternal health consequences. (See  <a class="medical medical_review" href="/z/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Potential issues in pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Preconception counseling, evaluation, and care'</a>.)</p><p></p><p class="bulletIndent1">Underweight females (especially those with eating disorders) are at increased risk for anovulatory infertility and pregnancy complications. In one large cohort study, females with a suboptimal BMI had a 20 percent increase in risk for preterm birth and a 40 percent increase in risk of having a small for gestational age infant [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4852.html" rel="external">"Eating disorders in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication changes or discontinuation</strong> to avoid use of teratogens  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 11</a>). (See <a class="local">'Resources'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of environmental teratogens</strong>  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 11</a>). (See <a class="local">'Resources'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease optimization</strong> (refer to individual topic reviews on each disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral changes</strong> (eg, hand washing and other hygienic measures; avoiding consumption of undercooked meats and unpasteurized foods) can reduce the risk of acquiring infections, such as toxoplasmosis, cytomegalovirus, and listeriosis. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/4810.html" rel="external">"Cytomegalovirus infection in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection"</a>.)</p><p></p><p class="bulletIndent1">Mosquito avoidance measures (eg, clothing, repellants) are recommended to avoid arthropod-borne infections. (See  <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures", section on 'Pregnant women'</a>.)</p><p></p><p class="bulletIndent1">Exercise has many health benefits. Most patients should continue to exercise during pregnancy, with some modifications. (See  <a class="medical medical_review" href="/z/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a>.)</p><p></p><p class="bulletIndent1">A healthy diet has life-long benefits. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/130920.html" rel="external">"Nutrition in pregnancy: Assessment and counseling"</a>.)</p><p></p><p class="headingAnchor" id="H192321076"><span class="h2">Interventions for selected risks</span></p><p class="headingAnchor" id="H21"><span class="h3">Maternal medical problems</span><span class="headingEndMark"> — </span>Optimal management of maternal medical conditions, including changes in medications to those known to be safer in pregnancy, is important. Another key component is close follow-up and communication with specialist clinicians who are also involved in caring for the patient.</p><p>Some common or serious medical conditions other than diabetes (discussed above) that impact or are impacted by pregnancy are discussed briefly below; additional disorders are reviewed separately. (Refer to individual topic reviews on medical disorders, section on pregnancy.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> should be controlled prior to conception. Treatment is initiated at a blood pressure threshold of 140/90 mmHg using the fewest medications at the lowest effective dose to maintain blood pressure below this level. Individuals Certain agents, such as ACE inhibitors and ARBs, should be avoided in pregnancy, as their use at any stage of pregnancy is associated with adverse effects on the fetus. Patients who are on any of these agents should be advised to switch to agents whose safety in pregnancy is established. (See  <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">"Chronic hypertension in pregnancy: Prenatal and postpartum care"</a> and  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p></p><p class="bulletIndent1">Individuals who have long-standing or poorly controlled hypertension should be evaluated for end-organ effects (eg, ventricular hypertrophy, retinopathy, renal insufficiency) [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma</strong> should be under good control prior to attempting conception. If necessary, the use of steroids (inhaled and systemic) in pregnancy is generally safe, particularly when compared with the risk of maternal acid base disturbance and fetal hypoxemia in the event of bronchospasm. (See  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a> and  <a class="medical medical_review" href="/z/d/html/554.html" rel="external">"Management of asthma during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid disease</strong> requires close monitoring of thyroid function as both hyper- and hypothyroidism can affect fertility and pregnancy outcome. Females who receive radioiodine should defer pregnancy for at least six months. (See  <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females with a history of <strong>seizures </strong>and those taking antiseizure medications should receive thorough information about the risks of pregnancy for mother and fetus, adjustments in their drug regimen (if appropriate), and <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation to reduce the risk of neural tube defects (dose depends on antiseizure medication regimen). In particular, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> should be discontinued if seizures can be adequately controlled with an alternative drug, since valproate appears to be a more potent teratogen than other antiseizure medications  (<a class="graphic graphic_figure graphicRef118230" href="/z/d/graphic/118230.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy can pose additional risks to females with <strong>cardiovascular disease</strong> (congenital or acquired) that should be addressed before conception. Cardiovascular disease is the most common cause of indirect maternal mortality and is responsible for over one-third of pregnancy-related maternal deaths [<a href="#rid55">55</a>]. For females with some cardiac conditions, pregnancy can be life-threatening and should be avoided. Patients taking statins are advised to discontinue them. Patients taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> are switched to heparin. (See  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.)</p><p></p><p class="bulletIndent1">Maternal cardiovascular health also has implications for offspring. In a multinational cohort study, poor maternal cardiovascular health metrics (as defined by BMI, blood pressure, total cholesterol level, glucose level, and smoking) at approximately 28 weeks of gestation was associated with poor cardiovascular health metrics in offspring examined at 10 to 14 years of age [<a href="#rid56">56</a>]. No single maternal metric drove the association, which may be related to epigenetic modifications in utero, as well as genetic susceptibility and household lifestyle. Improving maternal cardiovascular health metrics is beneficial for the mother and, if achieved before and maintained throughout pregnancy, may improve offspring cardiovascular health metrics as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For females with <strong>systemic lupus erythematosus</strong>, the prognosis is best when the disease has been quiescent for at least six months prior to pregnancy and the patient's underlying renal function is stable and normal or near normal. Maternal medications may need to be changed because of potential fetal risks. For example, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> increases the risk of first-trimester pregnancy loss and congenital malformations, including cleft lip and palate, as well as anomalies of the distal limbs, heart, esophagus, and kidneys. This medication should be avoided during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4679.html" rel="external">"Pregnancy in women with systemic lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females with <strong>inherited thrombophilias</strong> are at higher risk of thromboembolic complications during pregnancy because of pregnancy-associated changes in several coagulation factors; in some cases, they are at increased risk of adverse pregnancy outcome, as well. Indications for, and management of, anticoagulation should be addressed with a thrombosis specialist. (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ideally, any female with a <strong>history of anaphylaxis</strong> should be referred to an allergy specialist for evaluation prior to pregnancy. This is particularly important for those who experienced anaphylaxis in association with a previous medical or surgical procedure, as similar medications may be needed during labor and delivery. (See  <a class="medical medical_review" href="/z/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dental caries and other oral diseases</strong> (eg, periodontal disease) are common and may be associated with pregnancy complications, such as preterm delivery; thus, referral to a dentist is appropriate. (See  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Heritable diseases</span><span class="headingEndMark"> — </span>For couples at increased risk of offspring with a heritable disease, referral to a specialist in genetics is usually warranted to discuss the results of screening tests, risk of the disease in the fetus, the natural course of the disease, options regarding preimplantation and prenatal diagnosis and intervention, and reproductive alternatives. As options for prenatal diagnosis and reproductive alternatives are rapidly changing, a timely referral may be indicated even if the patient has had previous counseling. (See <a class="local">'Laboratory assessment'</a> above and  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p class="headingAnchor" id="H192323464"><span class="h3">Psychosocial issues</span><span class="headingEndMark"> — </span>Psychosocial stress, mental health, and financial issues should be identified and appropriate interventions taken with the help of a community resource specialist. It is particularly important to screen for the presence of intimate partner violence, lack of social support, and barriers to prenatal care [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/15294.html" rel="external">"Intimate partner violence: Diagnosis and screening"</a>.)</p><p>Maternal psychiatric illness should be identified and treated, as appropriate, because untreated or inadequately treated disease will result in maternal suffering and could lead to a variety of consequences, such as poor compliance with prenatal care, poor nutrition, substance abuse, or disturbed relationships between the mother and infant [<a href="#rid58">58</a>]. Ideally, the patient should wait until they have become euthymic, which may take 6 to 12 months, before attempting to conceive [<a href="#rid59">59</a>].</p><p>Drugs used to treat psychiatric disease can affect the fetus and neonate. Females who have been on medication and have mild or no symptoms for six or more months may be considered for medication taper and discontinuation (eg, decrease medication by 25 percent every one to two weeks) [<a href="#rid59">59</a>]. Some individuals may benefit from psychotherapy. Discontinuation of pharmacotherapy is generally not advised for individuals with a history of severe recurrent depressive disorders, psychosis, bipolar illness, psychiatric comorbidity requiring pharmacotherapy, or a history of suicidal ideation. (See  <a class="medical medical_review" href="/z/d/html/89067.html" rel="external">"Antenatal use of antidepressants and the potential risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Diet and supplements</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins, supplements</strong> – As discussed above (see <a class="local">'Core interventions'</a> above), all females planning pregnancy or capable of becoming pregnant should be counseled to take supplemental <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> to reduce the risk of having an infant with a neural tube defect [<a href="#rid60">60,61</a>], and possibly other congenital anomalies [<a href="#rid62">62</a>] and abruption [<a href="#rid63">63,64</a>]. The neural tube closes between 24 and 26 days after conception so folic acid supplementation after the diagnosis of pregnancy is usually too late to reduce the risk of neural tube defects. The most convenient method of folic acid supplementation is daily intake of a multivitamin containing 400 to 800 mcg of folic acid. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p></p><p class="bulletIndent1">Megavitamins, nonessential dietary supplements, and herbal preparations should be discontinued, given that the risk to the fetus from such substances has generally not been evaluated. Megadoses of <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> taken during early pregnancy have been associated with congenital anomalies [<a href="#rid65">65,66</a>]. Multivitamin preparations containing more than 5000 international units of vitamin A should be avoided (increased risk of teratogenesis at &gt;10,000 international units/day). (See  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements"</a>.)</p><p></p><p class="bulletIndent1">Many prenatal vitamins contain no iodine. Females planning pregnancy have been advised to supplement their diet with a daily oral multivitamin supplement that contains 150 to 250 mcg of iodine in the form of potassium iodide, although there is insufficient evidence of the benefits and harms of routine iodine supplementation. Using iodized salt (contains 95 mcg iodine per one-quarter teaspoon) and consuming seafood that is naturally rich in iodine are alternatives. (See  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Iodine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Healthy diet</strong> – A healthy diet is generally the same whether or not an individual is planning pregnancy, with some exceptions. (See  <a class="medical medical_review" href="/z/d/html/130920.html" rel="external">"Nutrition in pregnancy: Assessment and counseling", section on 'General principles of a healthy diet during pregnancy'</a>.)</p><p></p><p class="bulletIndent1">High caffeine intake should probably be avoided; experts suggest that females who are attempting to conceive (or who are pregnant) limit caffeine consumption to less than 200 to 300 mg per day. (See  <a class="medical medical_review" href="/z/d/html/406.html" rel="external">"Caffeine: Effects on reproductive outcomes in females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fish</strong> – The quantity and type of fish consumed should also be regulated and certain types of fish should be avoided during pregnancy and the preconception period due to concerns about possible teratogenic effects from environmental toxins, particularly mercury. Only cooked fish should be eaten. There is no clear evidence that n-3 (also known as omega-3) long chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) supplements during pregnancy improve offspring neurodevelopment or other outcomes. (See  <a class="medical medical_review" href="/z/d/html/431.html" rel="external">"Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/130920.html" rel="external">"Nutrition in pregnancy: Assessment and counseling", section on 'Guidelines for safe seafood consumption'</a>.)</p><p></p><p class="headingAnchor" id="H11575403"><span class="h3">Infertility, recurrent miscarriage, and adverse pregnancy outcome</span><span class="headingEndMark"> — </span>The general consensus among infertility experts is that infertility evaluation should be undertaken for couples who have not been able to conceive after 12 months of unprotected and frequent intercourse, but earlier evaluation should be undertaken based on medical history and physical findings and in females over 35 years of age  (<a class="graphic graphic_table graphicRef70415" href="/z/d/graphic/70415.html" rel="external">table 12</a>). (See  <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p>Ideally, the work-up for potential causes of adverse pregnancy outcome should be performed by the obstetrician-gynecologist as part of the antepartum or postpartum management of the affected pregnancy. Subsequent management depends on the cause. (Refer to individual topic reviews on miscarriage, recurrent pregnancy loss, preterm birth, preeclampsia, stillbirth, congenital anomalies, and other pregnancy complications.)</p><p class="headingAnchor" id="H2402470229"><span class="h1">MEASURES OF SUCCESSFUL PRECONCEPTION CARE</span><span class="headingEndMark"> — </span>A clinical workgroup of the National Preconception Health and Health Care Initiative proposed that achievement of the following nine targets at the first prenatal visit is indicative of quality preconception care [<a href="#rid67">67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of tobacco use</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of uncontrolled depression</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of sexually transmitted infections</p><p class="bulletIndent1"><span class="glyph">●</span>Teratogen avoidance</p><p class="bulletIndent1"><span class="glyph">●</span>Healthy weight (body mass index [BMI] &gt;18 and &lt;30 kg/m<sup>2</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> use beginning at least three months before conception</p><p class="bulletIndent1"><span class="glyph">●</span>Optimal glycemic control</p><p class="bulletIndent1"><span class="glyph">●</span>Planned pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>First prenatal visit before 12 weeks of gestation</p><p></p><p>Other groups have included other targets, such as reduction in low birth weight, small for gestational age, and preterm newborns [<a href="#rid44">44</a>] and postpartum use of a most or moderately effective method of contraception before planning another pregnancy. In a Pregnancy Risk Assessment Monitoring System (PRAMS) survey, older females (35<em> </em>to<em> </em>44 years), non-Hispanic Black females, and uninsured females were least likely to achieve one or more preconception health indicators [<a href="#rid68">68</a>]. Systemic efforts to improve preconception care may help these vulnerable populations as well. </p><p class="headingAnchor" id="H792785249"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Individuals should be counseled to make an appointment with an obstetric clinician as soon as they believe they are pregnant to accurately estimate the gestational age/delivery date and to initiate prenatal care. (See  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment"</a> and  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs"</a>.)</p><p class="headingAnchor" id="H328184506"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110427.html" rel="external">"Society guideline links: Immunizations in adults"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reproductive health planning</strong> – Cisgender women of childbearing age should develop a reproductive health plan. As part of routine health maintenance, they should be asked about their intention to become pregnant and offered contraception that meets their contraceptive needs. They should be made aware of fertility and pregnancy problems that increase with advancing age  (<a class="graphic graphic_table graphicRef70415" href="/z/d/graphic/70415.html" rel="external">table 12</a>). (See <a class="local">'Target population'</a> above and <a class="local">'Age'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals</strong> – The goals of preconception care are to (see <a class="local">'Risk assessment at the preconception office visit'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identify potential risks to the mother, fetus, and pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Educate the individual about these risks, options for intervention and management for risk reduction, and reproductive alternatives.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initiate interventions to provide optimum maternal, fetal, and pregnancy outcomes. Interventions include motivational counseling, disease optimization, and specialist referral.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception history</strong> – Any one of several commercially available paper and computerized questionnaires and record forms designed for obtaining a thorough preconception history will help in identifying risks to the pregnant individual and their pregnancy. A preconception history includes review of (see <a class="local">'History'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic diseases (eg, diabetes, hypertension, oral health)</p><p class="bulletIndent2"><span class="glyph">•</span>Medications known to be teratogens</p><p class="bulletIndent2"><span class="glyph">•</span>Reproductive history  (<a class="graphic graphic_table graphicRef78008" href="/z/d/graphic/78008.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic conditions and family history</p><p class="bulletIndent2"><span class="glyph">•</span>Substance use, including tobacco, alcohol, and nonprescribed drugs</p><p class="bulletIndent2"><span class="glyph">•</span>Infectious diseases and vaccinations  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef98092" href="/z/d/graphic/98092.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef74584" href="/z/d/graphic/74584.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 5</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Nutrition, <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> intake, and weight management</p><p class="bulletIndent2"><span class="glyph">•</span>Environmental hazards and toxins  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 11</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Family planning</p><p class="bulletIndent2"><span class="glyph">•</span>Social and mental health concerns</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical assessment</strong> – A key component of medical assessment is to identify use of medications (including over-the-counter and prescription drugs) that are teratogenic and may be stopped, should be stopped, or can be changed to one that is safer for the pregnant individual or fetus  (<a class="graphic graphic_table graphicRef73369" href="/z/d/graphic/73369.html" rel="external">table 11</a>). (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation </strong>(See <a class="local">'Laboratory assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for HIV, gonorrhea, chlamydia, syphilis  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 2</a>); hepatitis B and C  (<a class="graphic graphic_table graphicRef55052" href="/z/d/graphic/55052.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef98092" href="/z/d/graphic/98092.html" rel="external">table 4</a>); and other sexually transmitted infections is performed according to standard guidelines </p><p class="bulletIndent2"><span class="glyph">•</span>Document rubella immunity or lack of immunity</p><p class="bulletIndent2"><span class="glyph">•</span>Document varicella immunity or lack of immunity</p><p class="bulletIndent2"><span class="glyph">•</span>Screen for Chagas disease in females of reproductive age who were born in or lived in a region of Mexico or South or Central America with endemic Chagas disease  (<a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 5</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>Genetic carrier screening may be based upon the patient's or the potential biologic father's medical history or family history of heritable disease, ethnic origin, or patient request</p><p class="bulletIndent2"><span class="glyph">•</span>Screen for pregestational diabetes in individuals with risk factors for diabetes  (<a class="graphic graphic_table graphicRef122948" href="/z/d/graphic/122948.html" rel="external">table 6</a>) and check glycated hemoglobin (A1C) in individuals with pregestational diabetes</p><p class="bulletIndent2"><span class="glyph">•</span>Check a serum phenylalanine level if maternal phenylketonuria is known or suspected</p><p class="bulletIndent2"><span class="glyph">•</span>Test for latent tuberculosis in high-risk populations</p><p class="bulletIndent2"><span class="glyph">•</span>Check a lead level if the patient is at high risk of lead exposure or an increased lead level </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Core interventions</strong> – Core preconception interventions that can reduce the occurrence of congenital disorders, fetal growth abnormalities, and pregnancy complications include (see <a class="local">'Core interventions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> supplementation and intake of fortified foods</p><p class="bulletIndent2"><span class="glyph">•</span>Glycemic control in females with diabetes; screening for diabetes in females with risk factors; evaluation for and treatment of proliferative retinopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Control of phenylalanine levels in females with phenylketonuria</p><p class="bulletIndent2"><span class="glyph">•</span>Abstinence from alcohol and illicit drugs; nicotine and tetrahydrocannabinol (THC) cessation</p><p class="bulletIndent2"><span class="glyph">•</span>Achieve or maintain a healthy body mass index (BMI; 18.5 to 24.9 kg/m<sup>2</sup>)</p><p class="bulletIndent2"><span class="glyph">•</span>Medication changes to avoid use of teratogens</p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of environmental teratogens</p><p class="bulletIndent2"><span class="glyph">•</span>Disease optimization (see <a class="local">'Maternal medical problems'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Up-to-date vaccinations  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 2</a> and <a class="graphic graphic_table graphicRef81508" href="/z/d/graphic/81508.html" rel="external">table 10</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Behavioral changes to reduce the risk of acquiring infections, such as toxoplasmosis, cytomegalovirus, and listeriosis; to achieve 150 min/week or more of moderate-to-vigorous physical activity; and consume a healthy diet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing risk of heritable disorders</strong> – For females with a positive history for a heritable disease, referral to a specialist in genetic counseling is usually required to discuss carrier testing, the risk of genetic disease in the fetus, options regarding prenatal diagnosis and intervention, the natural course of the disease, and reproductive alternatives. (See <a class="local">'Heritable diseases'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Johnson K, Posner SF, Biermann J, et al. Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Mazza D, Chapman A, Michie S. Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. BMC Health Serv Res 2013; 13:36.</a></li><li><a class="nounderline abstract_t">Mwase-Musicha L, Chipeta MG, Stephenson J, Hall JA. How do women prepare for pregnancy in a low-income setting? Prevalence and associated factors. PLoS One 2022; 17:e0263877.</a></li><li><a class="nounderline abstract_t">Moos MK, Dunlop AL, Jack BW, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. Am J Obstet Gynecol 2008; 199:S280.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 762: Prepregnancy Counseling. Obstet Gynecol 2019; 133:e78. Reaffirmed 2021.</a></li><li><a class="nounderline abstract_t">Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.</a></li><li><a class="nounderline abstract_t">Nelson HD, Darney BG, Ahrens K, et al. Associations of Unintended Pregnancy With Maternal and Infant Health Outcomes: A Systematic Review and Meta-analysis. JAMA 2022; 328:1714.</a></li><li><a class="nounderline abstract_t">Moser R Jr, McCance KL, Smith KR. Results of a national survey of physicians' knowledge and application of prevention capabilities. Am J Prev Med 1991; 7:384.</a></li><li><a class="nounderline abstract_t">Conway T, Mason E, Hu TC. Attitudes, knowledge, and skills of internal medicine residents regarding pre-conception care. Acad Med 1994; 69:389.</a></li><li><a class="nounderline abstract_t">Conway T, Hu TC, Mason E, Mueller C. Are primary care residents adequately prepared to care for women of reproductive age? Fam Plann Perspect 1995; 27:66.</a></li><li><a class="nounderline abstract_t">Moos MK, Bangdiwala SI, Meibohm AR, Cefalo RC. The impact of a preconceptional health promotion program on intendedness of pregnancy. Am J Perinatol 1996; 13:103.</a></li><li><a class="nounderline abstract_t">Jack BW, Culpepper L, Babcock J, et al. Addressing preconception risks identified at the time of a negative pregnancy test. A randomized trial. J Fam Pract 1998; 47:33.</a></li><li><a class="nounderline abstract_t">Bernstein PS, Sanghvi T, Merkatz IR. Improving preconception care. J Reprod Med 2000; 45:546.</a></li><li><a class="nounderline abstract_t">Leuzzi RA, Scoles KS. Preconception counseling for the primary care physician. Med Clin North Am 1996; 80:337.</a></li><li><a class="nounderline abstract_t">Wensink MJ, Lu Y, Tian L, et al. Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study. Ann Intern Med 2022; 175:665.</a></li><li class="breakAll">Paternal exposures and effects on pregnancy outcome. UK Technology Information Service. Available at: https://www.medicinesinpregnancy.org/bumps/monographs/PATERNAL-EXPOSURES-AND-EFFECTS-ON-PREGNANCY-OUTCOME/ (Accessed on June 14, 2022).</li><li><a class="nounderline abstract_t">Bermas BL. Paternal safety of anti-rheumatic medications. Best Pract Res Clin Obstet Gynaecol 2020; 64:77.</a></li><li><a class="nounderline abstract_t">Stubblefield PG, Coonrod DV, Reddy UM, et al. The clinical content of preconception care: reproductive history. Am J Obstet Gynecol 2008; 199:S373.</a></li><li><a class="nounderline abstract_t">McDiarmid MA, Gardiner PM, Jack BW. The clinical content of preconception care: environmental exposures. Am J Obstet Gynecol 2008; 199:S357.</a></li><li><a class="nounderline abstract_t">Sathyanarayana S, Focareta J, Dailey T, Buchanan S. Environmental exposures: how to counsel preconception and prenatal patients in the clinical setting. Am J Obstet Gynecol 2012; 207:463.</a></li><li><a class="nounderline abstract_t">Shaw GM. Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature. Bioelectromagnetics 2001; Suppl 5:S5.</a></li><li class="breakAll">Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP) http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm#Tab3 (Accessed on November 07, 2013).</li><li><a class="nounderline abstract_t">Forsyth CJ, Manne-Goehler J, Bern C, et al. Recommendations for Screening and Diagnosis of Chagas Disease in the United States. J Infect Dis 2022; 225:1601.</a></li><li><a class="nounderline abstract_t">Solomon BD, Jack BW, Feero WG. The clinical content of preconception care: genetics and genomics. Am J Obstet Gynecol 2008; 199:S340.</a></li><li><a class="nounderline abstract_t">Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010; 376:1417.</a></li><li class="breakAll">NIOSH. Understanding blood lead levels https://www.cdc.gov/niosh/topics/ables/ReferenceBloodLevelsforAdults.html.</li><li><a class="nounderline abstract_t">Korenbrot CC, Steinberg A, Bender C, Newberry S. Preconception care: a systematic review. Matern Child Health J 2002; 6:75.</a></li><li><a class="nounderline abstract_t">Williams L, Zapata LB, D'Angelo DV, et al. Associations between preconception counseling and maternal behaviors before and during pregnancy. Matern Child Health J 2012; 16:1854.</a></li><li><a class="nounderline abstract_t">Elsinga J, de Jong-Potjer LC, van der Pal-de Bruin KM, et al. The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy. Womens Health Issues 2008; 18:S117.</a></li><li><a class="nounderline abstract_t">Floyd RL, Sobell M, Velasquez MM, et al. Preventing alcohol-exposed pregnancies: a randomized controlled trial. Am J Prev Med 2007; 32:1.</a></li><li><a class="nounderline abstract_t">Hood KK. Preconception counseling for adolescent females with type 1 diabetes: the READY-Girls Program. Curr Diab Rep 2010; 10:393.</a></li><li><a class="nounderline abstract_t">Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care 2006; 29:1744.</a></li><li><a class="nounderline abstract_t">Tripathi A, Rankin J, Aarvold J, et al. Preconception counseling in women with diabetes: a population-based study in the north of England. Diabetes Care 2010; 33:586.</a></li><li><a class="nounderline abstract_t">de Weerd S, Thomas CM, Cikot RJ, Steegers EA. Maternal smoking cessation intervention: targeting women and their partners before pregnancy. Am J Public Health 2001; 91:1733.</a></li><li><a class="nounderline abstract_t">Beckmann MM, Widmer T, Bolton E. Does preconception care work? Aust N Z J Obstet Gynaecol 2014; 54:510.</a></li><li><a class="nounderline abstract_t">Whitworth M, Dowswell T. Routine pre-pregnancy health promotion for improving pregnancy outcomes. Cochrane Database Syst Rev 2009; :CD007536.</a></li><li><a class="nounderline abstract_t">Tieu J, Middleton P, Crowther CA. Preconception care for diabetic women for improving maternal and infant health. Cochrane Database Syst Rev 2010; :CD007776.</a></li><li><a class="nounderline abstract_t">Lumley J, Chamberlain C, Dowswell T, et al. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2009; :CD001055.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2023; 330:454.</a></li><li><a class="nounderline abstract_t">Viswanathan M, Urrutia RP, Hudson KN, et al. Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2023; 330:460.</a></li><li><a class="nounderline abstract_t">Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001; 94:435.</a></li><li><a class="nounderline abstract_t">Winterbottom J, Smyth R, Jacoby A, Baker G. The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: what's the evidence? Epilepsy Behav 2009; 14:273.</a></li><li><a class="nounderline abstract_t">Drogari E, Smith I, Beasley M, Lloyd JK. Timing of strict diet in relation to fetal damage in maternal phenylketonuria. An international collaborative study by the MRC/DHSS Phenylketonuria Register. Lancet 1987; 2:927.</a></li><li><a class="nounderline abstract_t">Taneja S, Chowdhury R, Dhabhai N, et al. Impact of a package of health, nutrition, psychosocial support, and WaSH interventions delivered during preconception, pregnancy, and early childhood periods on birth outcomes and on linear growth at 24 months of age: factorial, individually randomised controlled trial. BMJ 2022; 379:e072046.</a></li><li><a class="nounderline abstract_t">Wang S, Mitsunami M, Ortiz-Panozo E, et al. Prepregnancy Healthy Lifestyle and Adverse Pregnancy Outcomes. Obstet Gynecol 2023; 142:1278.</a></li><li><a class="nounderline abstract_t">Lum KJ, Sundaram R, Buck Louis GM. Women's lifestyle behaviors while trying to become pregnant: evidence supporting preconception guidance. Am J Obstet Gynecol 2011; 205:203.e1.</a></li><li><a class="nounderline abstract_t">Oza-Frank R, Kachoria R, Keim SA, Klebanoff MA. Provision of specific preconception care messages and associated maternal health behaviors before and during pregnancy. Am J Obstet Gynecol 2015; 212:372.e1.</a></li><li><a class="nounderline abstract_t">Chandranipapongse W, Koren G. Preconception counseling for preventable risks. Can Fam Physician 2013; 59:737.</a></li><li><a class="nounderline abstract_t">Shannon GD, Alberg C, Nacul L, Pashayan N. Preconception health care and congenital disorders: mathematical modelling of the impact of a preconception care programme on congenital disorders. BJOG 2013; 120:555.</a></li><li><a class="nounderline abstract_t">Khan SS, Brewer LC, Canobbio MM, et al. Optimizing Prepregnancy Cardiovascular Health to Improve Outcomes in Pregnant and Postpartum Individuals and Offspring: A Scientific Statement From the American Heart Association. Circulation 2023; 147:e76.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S282.</a></li><li><a class="nounderline abstract_t">Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion, Number 802. Obstet Gynecol 2020; 135:e167.</a></li><li><a class="nounderline abstract_t">Tabet M, Flick LH, Tuuli MG, et al. Prepregnancy body mass index in a first uncomplicated pregnancy and outcomes of a second pregnancy. Am J Obstet Gynecol 2015; 213:548.e1.</a></li><li><a class="nounderline abstract_t">Dunlop AL, Jack BW, Bottalico JN, et al. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol 2008; 199:S310.</a></li><li><a class="nounderline abstract_t">Kotit S, Yacoub M. Cardiovascular adverse events in pregnancy: A global perspective. Glob Cardiol Sci Pract 2021; 2021:e202105.</a></li><li><a class="nounderline abstract_t">Perak AM, Lancki N, Kuang A, et al. Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence. JAMA 2021; 325:658.</a></li><li><a class="nounderline abstract_t">Klerman LV, Jack BW, Coonrod DV, et al. The clinical content of preconception care: care of psychosocial stressors. Am J Obstet Gynecol 2008; 199:S362.</a></li><li><a class="nounderline abstract_t">Frieder A, Dunlop AL, Culpepper L, Bernstein PS. The clinical content of preconception care: women with psychiatric conditions. Am J Obstet Gynecol 2008; 199:S328.</a></li><li><a class="nounderline abstract_t">Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:703.</a></li><li><a class="nounderline abstract_t">U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:626.</a></li><li class="breakAll">National Health Service. Vitamins and nutrition in pregnancy. http://www.nhs.uk/conditions/pregnancy-and-baby/pages/vitamins-minerals-supplements-pregnant.aspx (Accessed on November 05, 2012).</li><li><a class="nounderline abstract_t">Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28:680.</a></li><li><a class="nounderline abstract_t">Nilsen RM, Vollset SE, Rasmussen SA, et al. Folic acid and multivitamin supplement use and risk of placental abruption: a population-based registry study. Am J Epidemiol 2008; 167:867.</a></li><li><a class="nounderline abstract_t">Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta 1999; 20:519.</a></li><li><a class="nounderline abstract_t">Oakley GP Jr, Erickson JD. Vitamin A and birth defects. Continuing caution is needed. N Engl J Med 1995; 333:1414.</a></li><li><a class="nounderline abstract_t">Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.</a></li><li><a class="nounderline abstract_t">Frayne DJ, Verbiest S, Chelmow D, et al. Health Care System Measures to Advance Preconception Wellness: Consensus Recommendations of the Clinical Workgroup of the National Preconception Health and Health Care Initiative. Obstet Gynecol 2016; 127:863.</a></li><li><a class="nounderline abstract_t">Robbins C, Boulet SL, Morgan I, et al. Disparities in Preconception Health Indicators -  Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014. MMWR Surveill Summ 2018; 67:1.</a></li></ol></div><div id="topicVersionRevision">Topic 448 Version 92.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16617292" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23368720" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35286337" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : How do women prepare for pregnancy in a low-income setting? Prevalence and associated factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081422" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575679" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ACOG Committee Opinion No. 762: Prepregnancy Counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018121" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Unintended pregnancy in the United States: incidence and disparities, 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318133" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Associations of Unintended Pregnancy With Maternal and Infant Health Outcomes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1790047" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Results of a national survey of physicians' knowledge and application of prevention capabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166923" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Attitudes, knowledge, and skills of internal medicine residents regarding pre-conception care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7796898" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Are primary care residents adequately prepared to care for women of reproductive age?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672181" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The impact of a preconceptional health promotion program on intendedness of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Addressing preconception risks identified at the time of a negative pregnancy test. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10948464" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Improving preconception care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614177" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Preconception counseling for the primary care physician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344380" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35344380" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31727565" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Paternal safety of anti-rheumatic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The clinical content of preconception care: reproductive history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081430" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The clinical content of preconception care: environmental exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22440197" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Environmental exposures: how to counsel preconception and prenatal patients in the clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170114" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170114" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34623435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recommendations for Screening and Diagnosis of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081428" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The clinical content of preconception care: genetics and genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20971365" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phenylketonuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20971365" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phenylketonuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12092984" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Preconception care: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22173331" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Associations between preconception counseling and maternal behaviors before and during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059545" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Preventing alcohol-exposed pregnancies: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20820956" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Preconception counseling for adolescent females with type 1 diabetes: the READY-Girls Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16873774" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prepregnancy care and pregnancy outcomes in women with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040652" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Preconception counseling in women with diabetes: a population-based study in the north of England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684586" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Maternal smoking cessation intervention: targeting women and their partners before pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132235" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Does preconception care work?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821424" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Routine pre-pregnancy health promotion for improving pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154385" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Preconception care for diabetic women for improving maternal and infant health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588322" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interventions for promoting smoking cessation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37526713" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37526714" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493721" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19100341" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: what's the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2889860" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Timing of strict diet in relation to fetal damage in maternal phenylketonuria. An international collaborative study by the MRC/DHSS Phenylketonuria Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36288808" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Impact of a package of health, nutrition, psychosocial support, and WaSH interventions delivered during preconception, pregnancy, and early childhood periods on birth outcomes and on linear growth at 24 months of age: factorial, individually randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37826849" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prepregnancy Healthy Lifestyle and Adverse Pregnancy Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658667" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Women's lifestyle behaviors while trying to become pregnant: evidence supporting preconception guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25446665" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Provision of specific preconception care messages and associated maternal health behaviors before and during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23851536" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preconception counseling for preventable risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331865" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Preconception health care and congenital disorders: mathematical modelling of the impact of a preconception care programme on congenital disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36780391" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Optimizing Prepregnancy Cardiovascular Health to Improve Outcomes in Pregnant and Postpartum Individuals and Offspring: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078583" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217978" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Management of Women With Phenylalanine Hydroxylase Deficiency (Phenylketonuria): ACOG Committee Opinion, Number 802.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26103529" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prepregnancy body mass index in a first uncomplicated pregnancy and outcomes of a second pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081425" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The clinical content of preconception care: women with chronic medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036091" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cardiovascular adverse events in pregnancy: A global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33591345" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081431" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The clinical content of preconception care: care of psychosocial stressors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081426" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The clinical content of preconception care: women with psychiatric conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19701065" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414842" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414842" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022907" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187445" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Folic acid and multivitamin supplement use and risk of placental abruption: a population-based registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452905" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477124" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vitamin A and birth defects. Continuing caution is needed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477116" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Teratogenicity of high vitamin A intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27054935" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Health Care System Measures to Advance Preconception Wellness: Consensus Recommendations of the Clinical Workgroup of the National Preconception Health and Health Care Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346340" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Disparities in Preconception Health Indicators - Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
